See every side of every news story
Published loading...Updated

US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks

  • Ozempic and Wegovy are now included in Medicare's list of drugs for price negotiations, according to the Biden Administration.
  • The negotiations will involve 15 drugs and could save taxpayers billions, as stated by Health and Human Services Secretary Xavier Becerra.
  • Medicare's spending on Ozempic and Wegovy reached $14.4 billion from November 2023 to October 2024, highlighting the need for price negotiations.
  • The negotiated prices for these drugs will not take effect until 2027, as noted in the announcement.
Insights by Ground AI
Does this summary seem wrong?

213 Articles

All
Left
26
Center
70
Right
23
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 59% of the sources are Center
59% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Portfolio.hu broke the news in on Friday, January 17, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.